Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is back in focus after the FDA accepted its supplemental New Drug Application for nebulized Tyvaso in idiopathic pulmonary fibrosis, a regulatory milestone that puts fresh attention on the drug pipeline.

Recent trading shows that momentum in United Therapeutics has cooled in the short term, with the 30-day share price return down 4.31% and the 90-day share price return down 7.07%. At the same time, the 1-year total shareholder return of 27.82% and 3-year total shareholder return of 127.95% reflect a much stronger longer-term story that this latest FDA update and recent conference appearances put back under the spotlight.

Spot 31 high quality undervalued stocks that, like United Therapeutics after this Tyvaso update, pair active drug pipelines with solid balance sheets and have recently fallen off the short-term momentum radar.

United Therapeutics is trading well below recent highs despite FDA progress and visible cash returns, which raises a simple question. Are you looking at a business reset, or just a sentiment reset, as you weigh the valuation next?

Most Popular Narrative: 23.8% Undervalued

Against a last close of $506.82, the most followed narrative for United Therapeutics pegs fair value at $665.23, putting the recent pullback against a much higher long run cash flow story.

The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine, which can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.

Read the complete narrative.

Want to know what this narrative is really baking in? The projected top line curve, the margin profile, even the share count path all matter. The fair value hangs on a specific mix of growth, profitability, and required return that might not match your own assumptions.

Result: Fair Value of $665.23 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the narrative can unravel quickly if key trials such as TETON or ADVANCE OUTCOMES disappoint, or if competition in pulmonary arterial hypertension bites harder than expected.

Find out about the key risks to this United Therapeutics narrative.

Next Steps

Confident about the tone of this United Therapeutics story or still on the fence as new data and trials come through? Act quickly, test the assumptions under pressure, and then weigh them against the 5 key rewards.

Looking for more United Therapeutics sized ideas?

Do not let your research stop with United Therapeutics. Broaden your watchlist with fresh ideas that match different risk levels, income needs, and value preferences.

• Target potential mispricings and seek quality at a discount as you scan the 31 high quality undervalued stocks.
• Build a steadier income stream by reviewing the 6 dividend fortresses.
• Lower the bumpiness of your portfolio and concentrate on resilience with the 10 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com